Ceftram

There is no image.

Ceftazidime

Method of action: Bactericidal, Bactericidal Broad Spectrum

Treatment option: Abscess, Bacterial Meningitis, Bacteremia, Bronchitis, Bronchiectasis, Bursitis, Gonorrhea, Infection, Infection,Bacterial, Infection,Urinary Tract

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ceftram

Quick Facts

Property	Description
Active ingredient	Ceftazidime
Form	Powder or solution for injection
Pharmacological class	beta-lactam antibiotic; Third-generation cephalosporin
General purpose	Elimination of systemic bacterial infections
Origin	Semisynthetic

What Type of Antibiotic is Ceftram (Ceftazidime)?

Ceftram is a potent, semisynthetic antibacterial drug used exclusively to treat serious bacterial infections, with its therapeutic efficacy provided by the core compound, Ceftazidime. It belongs to the major pharmacological group known as the cephalosporin antibiotics, and is classified specifically as a third-generation cephalosporin. This classification establishes it within a group of highly effective agents used against a broad spectrum of pathogens. This designation is crucial as it grants the drug enhanced stability against many of the beta-lactamase enzymes bacteria use as a defense mechanism, a property clinically recognized for maintaining efficacy against difficult-to-treat organisms. The general therapeutic purpose of Ceftram is to provide swift, dependable systemic coverage, for instance, in the management of severe respiratory or abdominal infections.

Composition and Physical Form of Ceftram

The essential active substance in Ceftram is Ceftazidime, which is supplied as a single-ingredient product formulated solely for parenteral administration via injection. Ceftram is typically available as a dry-powdered mixture for injection, which requires mixing with a sterile aqueous vehicle before use, or as a premixed solution ready for infusion. This physical form confirms that Ceftram is not an oral medication; its intravenous or intramuscular route of administration is necessary to achieve the high, sustained concentration in the bloodstream required to effectively treat serious, deep-seated infections.

How Does Ceftram Work (Basic Principle)?

Ceftram is a bactericidal agent, meaning its primary function is to directly kill susceptible bacteria rather than just slowing their growth. Its mechanism involves disrupting the bacteria's ability to build their protective cell wall by binding to and inactivating crucial bacterial enzymes known as penicillin-binding proteins (PBPs). This targeted disruption causes structural failure, leading to the rapid destruction and death of the bacterial cell, which is the basic principle behind how the drug helps to clear an infection.

What side effects are possible with Ceftram?

Possible Side Effects and Safety Information

Regulatory documents classify the possible adverse reactions associated with Ceftram (Ceftazidime) according to the frequency and the specific body system affected. Adverse events are grouped under standard System-Organ Classes (SOCs), which include Gastrointestinal Disorders, Nervous System Disorders, Blood and Lymphatic System Disorders, and Skin and Subcutaneous Tissue Disorders.

Adverse Reaction Frequency and System

The most frequently observed adverse reactions are classified as Common (up to 1 in 10 people) and include local reactions such as phlebitis or pain at the injection/infusion site, as well as blood changes like eosinophilia and thrombocytosis. Reactions classified as Uncommon (up to 1 in 100 people) typically involve gastrointestinal effects such as diarrhoea, nausea, vomiting, or headache and rash.

Serious Adverse Reactions

The official safety labels document specific, low-incidence events considered clinically significant. These Serious Adverse Reactions include life-threatening Anaphylaxis and severe cutaneous adverse reactions (SCARs), such as Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN). The labels also note the potential for Antibacterial Agent-Associated Colitis, including pseudomembranous colitis.

Population-Specific Safety Considerations

A critical safety consideration documented in regulatory sources relates to Renal Impairment. In patients with reduced kidney function, there is an increased risk of specific neurological adverse events, including seizures, encephalopathy, and coma, due to the reduced clearance and accumulation of the drug. The labels also note that certain severe cutaneous reactions may manifest at the initiation of treatment, while colitis may occur subsequent to treatment administration.

Ceftram is contraindicated in individuals with a known hypersensitivity to the active ingredient, other cephalosporin class antibiotics, or any other beta-lactam antibacterial agents.

Overdose and Emergency Response

Overdose and When to Seek Help

Ceftram Overdose: Official Regulatory Information

Overdosage with Ceftram is defined by specific clinical manifestations and mandates immediate emergency action, as documented in official regulatory labeling.

Documented Overdose Presentations

Official regulatory information describes overdose presentations that primarily affect the gastrointestinal and central nervous systems (CNS). Documented symptoms include nausea, vomiting, and diarrhea, alongside CNS signs such as tremor, myoclonus, and seizures (convulsions). Severe overdosage may escalate to serious outcomes like encephalopathy and coma.

Required Emergency Action

Immediate Medical Attention is Required: The official label explicitly instructs patients and caregivers to seek immediate emergency medical attention for any suspected or confirmed Ceftram overdose. Urgent help must be secured if severe symptoms, such as seizures or loss of consciousness, are observed.

Management Strategy: The regulatory profile confirms that no specific chemical antidote is known for Ceftram overdosage. Management is supportive and symptomatic, prioritizing the cessation of the drug, maintenance of vital functions, and control of CNS hyper-excitability.

Population-Specific Risk

Official warnings highlight that patients with impaired renal function are at a specifically increased risk of experiencing severe CNS toxicity, including seizures, due to reduced drug clearance. This population requires close monitoring if overdose is suspected.

Therapeutic Uses of Ceftram

Ceftram is approved to address specific bacterial infections. Its primary function is to support the management of symptoms associated with these conditions, which include fever, discomfort, and inflammation. The medication is commonly utilized for the therapeutic management of several types of respiratory tract infections, such as certain forms of pneumonia and bronchitis; skin and soft tissue infections, which may involve localized redness or swelling; and certain urinary tract infections.

The goal of treatment with Ceftram is to assist the body's natural processes in resolving the infection, leading to a noticeable improvement in the patient’s overall well-being. By focusing on the source of the infection, Ceftram helps mitigate the severity of related discomfort and supports a return to baseline health.

Quick Fact: Supports management of infection-related symptoms and discomfort.

Eligibility and Restrictions for Use

Eligibility Map: Official Regulatory Information

This section outlines the populations for whom Ceftram is contraindicated, restricted, or requires special consideration, based solely on governmental regulatory documents for cephalosporin-class antibacterials.

Eligibility Classification	Details (Stated in Regulatory Documents)
Populations Contraindicated	Patients with a known, severe hypersensitivity reaction (e.g., anaphylaxis, serious allergic rash) to the drug substance Ceftram or to any member of the cephalosporin class of antibacterials.
Age-Related Restrictions	Use not established for infants and pediatric patients less than six months of age. Use is generally allowed for adults and pediatric patients six months and older.
Condition-Specific Restrictions	Requires dose adjustment and careful consideration in patients with markedly compromised renal function (e.g., Creatinine clearance <60 mL/min or <30 mL/min, depending on severity), as the drug is primarily eliminated by the kidneys.
Pregnancy/Lactation Status	Use during pregnancy is generally restricted to situations where it is clearly needed. For lactating mothers, consideration should be given to temporarily discontinuing nursing during treatment due to potential drug exposure in the infant.

Overall Eligibility Profile: Regulatory guidelines establish a clear prohibition against use for patients with a documented allergy to cephalosporin antibiotics. Eligibility is also formally constrained by age, with the drug's safety and efficacy not established in the youngest infant population. Use in patients with poor kidney function is permitted, but the official regulatory information mandates a restricted use profile involving a necessary dosage modification to prevent accumulation of the drug.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Ceftram (often referenced as Ceftriaxone in regulatory documents) has specific, officially documented interactions that primarily relate to physical incompatibility and potential pharmacodynamic effects, as described in authoritative government labeling.

Critical Incompatibility and Restrictions

Ceftram must never be mixed or administered simultaneously with calcium-containing solutions (such as Ringer's solution or Hartmann's solution) in the same intravenous line due to the risk of ceftriaxone-calcium salt precipitation. This interaction is considered contraindicated in neonates (patients up to 28 days of age) regardless of the route or time of administration, due to reports of fatal precipitation in the lungs and kidneys.

Pharmacokinetic Notes

Unlike many other medications, the elimination of Ceftram is not significantly inhibited or induced by Probenecid, and major interactions via the CYP450 enzyme system are not typically cited in the core prescribing information.

Mechanism of Action

Molecular Inactivation of Bacterial Cell Wall Builders

Ceftram is a beta-lactam agent that exerts a bactericidal effect through a mechanism targeting Penicillin-Binding Proteins (PBPs), bacterial transpeptidase enzymes required for cell wall assembly. The drug acts as an irreversible covalent inhibitor, physically binding to the PBP active site to halt the transpeptidation process that links the components of the wall.

The Cascade of Cell Wall Disruption and Lysis

The molecular inhibition of PBPs immediately disrupts the bacterial peptidoglycan synthesis pathway, leading to a defective cell wall structure. This failure, coupled with the drug's effect of triggering bacterial autolytic enzymes, causes the cell to lose its ability to withstand internal pressure. This specific mechanistic cascade culminates in irreversible cellular lysis and the overall bactericidal effect.

Mechanistic Resistance Profile

A characteristic of this mechanism is its intrinsic stability against many common beta-lactamase enzymes. This feature maintains the integrity of the molecule's action against those enzymes, ensuring PBP targets can be inactivated.

Dosage and Administration Information

How to Use Ceftram: Administration Guidelines

Ceftram (ceftazidime) is administered exclusively by injection. The dry powder product requires professional reconstitution and dilution with a sterile aqueous vehicle prior to use.

Routes and Timing

Administration Route	Typical Administration Time	Frequency Pattern
Intravenous (IV) Injection	Over 3 to 5 minutes	Every 8 or 12 hours
Intravenous (IV) Infusion	Over 20 to 30 minutes	Every 8 or 12 hours
Deep Intramuscular (IM) Injection	Into a large muscle mass	Every 8 or 12 hours

Standard Dosing and Adjustments

For adults with normal renal function, the recommended unit dose typically ranges from 500 mg to 2 grams, administered every 8 or 12 hours. The highest labeled dose for severe infections, such as meningitis, is 2 grams every 8 hours, not to exceed a total of 6 grams per day.

Population-Specific Rules

Renal Impairment: Because Ceftram is eliminated by the kidneys, the dosage must be reduced in patients with impaired renal function (creatinine clearance CrCl le 50 mL/min). Following an initial 1 gram loading dose, maintenance doses are reduced and intervals are extended, potentially to every 24 or 48 hours.
Older Adults: The total daily dose for patients over 80 years of age should not normally exceed 3 grams.
Pediatric Dosing: Dosage for children (over 1 month to 12 years) is determined by body weight, typically 30 to 50 mg/kg given every 8 hours. Treatment generally continues for at least 48 hours after signs of the infection have disappeared.

Recent Clinical Evidence

Research evidence / Overview of Studies for Ceftram

Ceftram (ceftazidime) has been studied extensively in clinical trials and systematic reviews, primarily focusing on its clinical evaluation in the management of serious bacterial infections caused by specific Gram-negative organisms. This overview summarizes the structure of that evidence, describing the types of studies conducted, the outcomes measured, and the current research limitations, without providing medical advice or treatment recommendations.

Evidence for Complicated Urinary Tract and Intra-Abdominal Infections

Research exploring Ceftram's role in managing complex infections of the urinary tract (cUTI) and complicated intra-abdominal infections (cIAI) largely relies on short-term Randomized Controlled Trials (RCTs). These studies were used to explore and measure how patients’ symptoms changed during the period of treatment. The core evidence describes patterns of measured symptom change and microbiological clearance at a specified follow-up visit. For cIAI, the research consistently described Ceftram being administered alongside another agent, consistent with the need to target the full range of bacteria involved. What remains uncertain is the applicability of older, single-agent Ceftazidime data to many highly resistant bacteria today.

Evidence for Lower Respiratory Tract Infections

Research on Ceftram for lung infections, such as Hospital-Acquired Pneumonia (HAP) and Ventilator-Associated Pneumonia (VAP), has included Phase 3 randomized trials that compared Ceftazidime to other standard treatments. Studies in this area examined outcomes related to the change in respiratory symptoms, the clearance of Gram-negative bacteria from the lungs, and 28-day mortality. Research using Ceftazidime alone for contemporary multi-drug resistant (MDR) pneumonia is limited. The research focus in this area has largely shifted to evaluating the newer Ceftazidime combination product, which was designed to address resistance mechanisms.

Remaining Uncertainties and Research Gaps

Clinical research for Ceftram focuses primarily on short-term outcomes. The follow-up durations for the primary efficacy measures are generally limited, meaning that long-term effects are not fully established by the core clinical trials. Evidence concerning the durability of the microbiological response is largely absent from the main regulatory evidence. Furthermore, the evidence for bacteremia relies on exploratory sub-set analyses of larger trials, not dedicated primary RCTs, meaning subgroup findings are uncertain due to small size and heterogeneity.

Key Studies & References Ceftazidime: Drug Information - Summary of Therapeutic Uses and Clinical Pharmacology (Uptodate/Lexicomp Monograph)

Frequently Asked Questions (FAQ)

Common questions about Ceftram (FAQ)

Q: What is the main role of Ceftram?

A: Ceftram is an antibiotic medicine. According to official product information, its main role is to treat infections caused by certain types of bacteria, specifically Gram-negative bacteria. It works by killing or stopping the growth of these susceptible bacterial organisms.

Q: How long does Ceftram take to start working after the first dose?

A: Official information from regulatory documents indicates that Ceftram has a rapid onset of action against the bacteria. For example, when used for respiratory infections, the maximum concentration in the blood is often reached within 1–2 hours after an intravenous (IV) dose. Its activity against the target bacteria is initiated once it reaches therapeutic concentrations in the bloodstream.

Q: Is Ceftram effective against many different types of bacteria?

A: Studies and official information indicate that Ceftram has a broad spectrum of activity against many disease-causing bacteria. It is noted to have significant activity against many Gram-negative bacteria, including Pseudomonas aeruginosa. However, it is not active against all types of bacteria, such as those that produce an enzyme called metallo-beta-lactamase.

Q: Can Ceftram be used to treat infections in the lungs, like pneumonia?

A: Yes, Ceftram is officially indicated for the treatment of various serious infections. This includes treating lower respiratory tract infections, such as hospital-acquired pneumonia, when these infections are caused by susceptible bacteria. Regulatory documents confirm its role in treating these types of serious conditions.

Q: Is Ceftram indicated for use in children with serious infections?

A: According to the official product information, Ceftram can be used in pediatric patients from two months of age for the treatment of certain serious infections. The use of Ceftram in this population has been established for specific indications. A healthcare professional determines the appropriate use based on the child's specific condition and weight.

Q: What are the common ways Ceftram is given to patients?

A: Regulatory documents state that Ceftram is administered intravenously (IV), meaning it is given directly into a vein. It can be given either as a slow infusion or as a direct injection. The precise method of administration is based on the patient's clinical situation, as determined by a healthcare provider.

Q: Are there any special warnings about the kidneys when using Ceftram?

A: Official information indicates that kidney function should be monitored in patients receiving Ceftram, particularly if they have pre-existing kidney problems or are receiving other kidney-toxic medicines. Regulatory documents mention that dosage adjustments may be necessary based on the patient's renal (kidney) function. This monitoring helps ensure appropriate dosing during treatment with Ceftram.

Q: What should I do if I miss an appointment to receive a dose of Ceftram?

A: Since Ceftram is typically administered in a healthcare setting, regulatory information does not provide 'at-home' instructions for a missed dose. If a scheduled dose is missed, patients are advised to contact their healthcare provider right away. The medical team will determine the best course of action to ensure the infection is treated effectively and maintain the therapeutic schedule.

How should Ceftram be stored and disposed of?

How to Store and Dispose of Ceftram?

Ceftram (Ceftazidime for Injection) requires specific conditions, which are documented in the official prescribing information to maintain its integrity and potency.

️ Storage Requirements

Condition	Requirement (Official Labeling)
Temperature (Dry Powder)	Store at 20 C to 25 C (Controlled Room Temperature).
Light Protection	The dry powder must be protected from light.
Frozen Solution	Should not be stored above -20 C and must not be refrozen after thawing.

Prepared solutions should be visually inspected; they must be clear, ranging from light yellow to amber, and free of particulate matter. The original container is typically a single-dose vial. There is no explicit instruction in the professional label regarding keeping the medicine out of the sight and reach of children. All unused Ceftram and related waste must be disposed of strictly in accordance with applicable local and federal regulations for pharmaceutical products.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.